CIK 0001840229 · <br>Emerging growth company
MiNK Therapeutics, Inc.
Sign in to watch- Ticker
- INKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 212-994-8250
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
- 10-Q Report Quarterly Report
- 8-K Event Shareholder vote results
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 10,157 shares (grant or award)
- 4 Grant or award Director acquired 10,086 shares (grant or award)
- 4 Grant or award Director acquired 8,736 shares (grant or award)
- 4 Grant or award Director acquired 7,955 shares (grant or award)
- 4 Grant or award Director acquired 8,168 shares (grant or award)
- 4/A Insider Changes in Ownership
- 4/A Insider Changes in Ownership
- 4/A Other disposition 10% owner disposed of 5,006,397 shares (other)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 45,426 shares at an average $1.47 ($66,644)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Director sold 100,000 shares at $0.95 ($94,850)
Page 9 of 14 · 267 filings